IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma.

1997637 citationsJournal Article

Authors

DG Maloney · Stanford University

A.J. Grillo-López

Abstract

IDEC-C2B8 chimeric anti-CD20 mAb therapy is well tolerated and has clinical activity in patients with relapsed B-cell lymphoma. The 375-mg/m2 dose has been selected for a phase II trial in patients with relapsed low-grade or follicular B-cell lymphoma.

Topics & Keywords

Lymphoma Diagnosis and Treatment Chronic Lymphocytic Leukemia Research Methemoglobinemia and Tumor Lysis Syndrome

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 15, Issue 10, pp. 3266-3274

DOI: 10.1200/jco.1997.15.10.3266

Field-Weighted Citation Impact: 17.26